Jazz Pharmaceuticals (NASDAQ:JAZZ) Updates FY 2025 Earnings Guidance

Jazz Pharmaceuticals (NASDAQ:JAZZ) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 22.500-24.000 for the period, compared to the consensus estimate of 24.000. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion. Jazz Pharmaceuticals also updated its FY 2025 guidance to 22.500-24.000 EPS.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. TD Cowen decreased their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday. Piper Sandler restated an “overweight” rating and issued a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday. Royal Bank of Canada reduced their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $140.00 to $150.00 in a research report on Wednesday. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $182.47.

Jazz Pharmaceuticals Stock Down 1.0 %

JAZZ traded down $1.50 during trading on Thursday, reaching $142.67. 796,368 shares of the stock traded hands, compared to its average volume of 698,451. The stock has a market cap of $8.63 billion, a price-to-earnings ratio of 20.15, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The stock’s 50-day simple moving average is $125.87 and its two-hundred day simple moving average is $118.62. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $148.06.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the transaction, the chief executive officer now directly owns 427,025 shares in the company, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 5,053 shares of company stock valued at $617,442. Corporate insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.